Dear Editor,Pancreatic cancer*is one of the deadliest cancers,with an overall 5-year survival rate of less than 10%unchanged over the last 40 years.Approximately 80-85%of patients are diagnosed as advanced stage,which...Dear Editor,Pancreatic cancer*is one of the deadliest cancers,with an overall 5-year survival rate of less than 10%unchanged over the last 40 years.Approximately 80-85%of patients are diagnosed as advanced stage,which are not eligible for curative surgery.1 Therapeutic options for advanced pancreatic cancer patients are still chemotherapy drugs with limited outcomes to improve patient survival and life quality.展开更多
基金This work was supported by the grant from the National Natural Science Foundation of China(Grant No.81903108 to S.H.)the Key Project of Zhejiang Ministry of Science and Technology(Grant No.2021C03087 to T.X.)the Key Project of Hangzhou Ministry of Science and Technology(Grant No.20212013B03 to T.X.).We thank Pierre Baillargeon and Lina Deluca at Scripps for their help with compound management,and Shujuan Zhao at Hangzhou Normal University for proteomics analysis.
文摘Dear Editor,Pancreatic cancer*is one of the deadliest cancers,with an overall 5-year survival rate of less than 10%unchanged over the last 40 years.Approximately 80-85%of patients are diagnosed as advanced stage,which are not eligible for curative surgery.1 Therapeutic options for advanced pancreatic cancer patients are still chemotherapy drugs with limited outcomes to improve patient survival and life quality.
